Arthrosi Appoints John Leaman, M.D., to Its Board of Directors | PR Newswire [Video]

, /PRNewswire/ — Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate levels, flares and tophi in patients with gout, today announced the appointment of John Leaman, M.D., to its Board as an Independent Board Director.

“John brings more than a decade of experience in finance, M&A and corporate strategy, with a strong understanding of gout, and we are excited to welcome him to our Board of Directors,” said Litain Yeh, Ph.D., Founder and CEO of Arthrosi Therapeutics. “We believe that his insights and guidance will be invaluable as we continue to advance our pivotal Phase 3 program for AR882 and position the Company as a leader in treating gout, including tophaceous gout patients.”

John H. Leaman, M.D. is currently the Chief Financial Officer at Cellarity. During his tenure, he has helped oversee the close of a large pharma …